News | Endovascular Aortic Repair | May 12, 2021

Low Profile Thoracic Aortic Endograft Device Reduces Complications and Expands Patient Pool

Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in the treatment of descending thoracic aortic aneurysm or penetrating atherosclerotic ulcer (PAU) diseases.

May 12, 2021 — Preliminary results of a clinical trial, presented today at the AATS 101st Annual Meeting, showed that a new, low-profile thoracic aortic endograft is safe and effective in the treatment of descending thoracic aortic aneurysm or penetrating atherosclerotic ulcer (PAU) diseases. A multi-disciplinary team, led by both cardiac and vascular surgeons as co-investigators, conducted the study in 36 centers in the United States and Japan, enrolling patients between 2016 and 2019.

The trial aimed to measure safety and efficacy of the RELAYPro endovascular device, a second-generation product featuring a dramatically reduced profile and a non-bare stent (NBS) configuration. 

The prospective, international, non-blinded, non-randomized pivotal trial analyzed a primary safety endpoint of major adverse events (MAE) at 30 days (death, myocardial infarction, stroke, renal/respiratory failure, paralysis, bowel ischemia, procedural blood loss) and a primary effectiveness endpoint of treatment success at one year (technical success, patency, absence of aneurysm rupture, type I/III endoleaks, stent fractures, secondary interventions, aneurysm expansion, and migration). Treatment success at one year was 89.2 percent.  

“With a 3 to 4 French profile reduction, this second generation thoracic endograft device met the one year safety and effectiveness endpoints in a pivotal study for the treatment of patients with aneurysms of the descending thoracic aorta or PAUs,” explained Wilson Szeto, M.D., Professor of Surgery at the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center. “It is particularly positive to note that the reduction in profile and the availability of a non bare stents configuration will expand the population of patients who can be treated with the device and reduces complications.” 

In this study, the vast majority of patients in the United States were treated with a percutaneous approach, which can dramatically reduce surgical complications associated with higher profile devices requiring surgical cutdown for deployment.  At one year follow up, patients demonstrated a low risk of mortality, endoleak or structural integrity concerns. Follow-up continues to five years and the device is currently being evaluated for approval by the FDA.

For more information: www.aats.org

Related Content

Medtronic Recalls Unused Valiant Navion Thoracic Stent Grafts
News | Endovascular Aortic Repair | February 23, 2021
February 23, 2021 — Medtronic has voluntarily issued a global recall of unused...
The researchers used high resolution cross-sectional imaging with CT or MRI to assess 225 men with abdominal aortic aneurysm. Follow-up lasted, on average, more than three years.  Slightly more than half of patients had an intraluminal thrombus. The aneurysms of those with intraluminal thrombus were larger at baseline and grew by a rate of 2 mm per year, twice as fast as the 1 mm per year growth rate in people without intraluminal thrombus.
News | Endovascular Aortic Repair | January 29, 2020
January 29, 2020 – The presence of a blood clot on the wall of the aorta in people with...
The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch.  #VIVA19 #VIVA2019

The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch. 

News | Endovascular Aortic Repair | November 11, 2019
November 7, 2019 — The Endospan Ltd.
Obese Patients Have More Post-Op Problems Following AAA Repair
News | Endovascular Aortic Repair | November 21, 2018
New research in the December edition of the Journal of Vascular Surgery suggests significant increase in morbidities in...
FDA Classifies Previous Endologix AFX Safety Notice as Class I Recall
News | Endovascular Aortic Repair | October 08, 2018
Endologix Inc. received notice that the U.S. Food and Drug Administration (FDA) has classified a voluntary recall...
The Gore TAG stent graft used in TEVAR aortic repair procedures for aneurysms.

The Gore TAG stent graft used for endovascular aortic aneurysm repair procedures.

Feature | Endovascular Aortic Repair | February 05, 2018 | Andrei Churyla, M.D., S. Chris Malaisrie, M.D.
Here are several considerations for physicians when choosing...
Endologix Receives IDE Approval for EVAS2 Confirmatory Clinical Study
News | Endovascular Aortic Repair | October 19, 2017
Endologix Inc. received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA...
New Paper Highlights Success of Advanced Treatments in Complex Aortic Aneurysm Repair
News | Endovascular Aortic Repair | May 23, 2017
Significant success has been achieved in treating complex proximal aneurysms using a combination of fenestrated and...
abdominal aortic aneurysm, AAA, gender differences, women vs. men, endovascular repair, Journal of Vascular Surgery study
News | Endovascular Aortic Repair | April 05, 2017
Following repair of abdominal aortic aneurysms (AAA), women appear to have more unfavorable outcomes than men in terms...